Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

NCT01590199 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: RAD001
DRUG: SOM230

Sponsor

Novartis Pharmaceuticals